Amount of qualified sufferers: CDEC reviewed the uncertainty in the amount of clients with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people who will be labeled as obtaining gentle or moderate sickness could possibly have a significant https://libmeldy18271.blogrelation.com/42205187/not-known-factual-statements-about-hemgenix